RxDoctor Payments Data

Sidney Plawes, MD

Cardiovascular Disease · Brooklyn, NYNPI 1679510119

Payments from drug & device makers

$2,617in general payments, 2019–2025

Across 137 payments — averaging $19.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$332
  • E.r. Squibb & Sons, L.L.C.$294
  • Amarin Pharma, Inc.$232
  • Bayer$201
  • Merck$164
  • Kestra Medical Technology Services, Inc.$143
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$2,60399%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,617 in reported general payments places this provider in the 55th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$670,623
Medicare patients
1,480
Services billed
12,366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban320$353,198
XareltoRivaroxaban107$123,917
EntrestoSacubitril/Valsartan95$108,865
JanuviaSitagliptin Phosphate54$57,727
JanumetSitagliptin Phos/Metformin Hcl34$37,752
JardianceEmpagliflozin18$25,484
FarxigaDapagliflozin Propanediol14$19,765
Metoprolol Succinate845$14,981
MultaqDronedarone Hcl12$8,492
Losartan Potassium651$6,648
Atorvastatin Calcium547$6,356
Rosuvastatin Calcium360$5,441
Amlodipine Besylate618$4,679
Nifedipine ErNifedipine83$3,227
Nebivolol Hcl39$3,012

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$332$353,198320 claims
Johnson & JohnsonXarelto$57$123,917107 claims
NovartisEntresto$16$108,86595 claims
MerckJanuvia, Janumet$164$95,47988 claims
Boehringer IngelheimJardiance$43$25,48418 claims
AstraZenecaFarxiga$122$19,76514 claims
Sanofi-aventis U.S. LLCMultaq$106$8,49212 claims
GSKArnuity Ellipta$142$2,51812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →